CN Patent

CN101085743B — 含氟烷氧基康普立停衍生物及制法和用途

Assigned to Zhejiang Dade Pharmaceutical Group Co Ltd · Expires 2012-02-15 · 14y expired

What this patent protects

本发明公开了一类新的康普立停(Combretastatin)衍生物及其制备方法。它具有下列结构式(I)，其在天然产物康普立停(Combretastatin)B芳环的4′位引入了含氟烷氧基，同时在它的3′位进行功能性化学修饰，导入氨基、硝基、卤素、烷氧基、磷酸盐、氨基酸侧链等。这些新衍生物具有更强的抑制微管蛋白集聚能力，可用于抗肿瘤和抗新生血管治疗。

USPTO Abstract

本发明公开了一类新的康普立停(Combretastatin)衍生物及其制备方法。它具有下列结构式(I)，其在天然产物康普立停(Combretastatin)B芳环的4′位引入了含氟烷氧基，同时在它的3′位进行功能性化学修饰，导入氨基、硝基、卤素、烷氧基、磷酸盐、氨基酸侧链等。这些新衍生物具有更强的抑制微管蛋白集聚能力，可用于抗肿瘤和抗新生血管治疗。

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

Patent Metadata

Patent number: CN101085743B
Jurisdiction: CN
Classification: —
Expires: 2012-02-15
Drug substance claim: No
Drug product claim: No
Assignee: Zhejiang Dade Pharmaceutical Group Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.